Between the Lines is an engaging 30- to 45-minute open discussion showcasing insightful and impactful perspectives from academic and community oncologists on published, peer-reviewed content.
Analyses on the Impact of Tumor Burden at Progression and Changes in IMDC Risk Scores in the CLEAR Trial Prognostic Insights in Advanced RCC With Lenvatinib Plus Pembrolizumab
Liso-cel vs Standard of Care With Salvage Chemotherapy Followed by ASCT as 2L Treatment in Patients With R/R LBCL: 3-year Follow-Up From Phase 3 TRANSFORM Study
Nivolumab Plus Chemotherapy vs Chemotherapy as First-Line Treatment of Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophageal Adenocarcinoma: Five- Year Follow-Up Results From CheckMate649
PALOMA-3: Subcutaneous Amivantamab + Lazertinib for EGFR+ NSCLC
Lenvatinib Plus Pembrolizumab vs Sunitinib in Advanced Renal Cell Carcinoma: Patterns of Progression and Subsequent Therapy in the CLEAR Trial
First-Line Nivolumab Plus Relatlimab vs Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data
CIRCULATE-Japan GALAXY: ctDNA-Based MRD Detection in Colorectal Cancer and Implications for Survival, Treatment, and Risk Stratification
Overall Survival With Ciltacabtagene Autoleucel vs Standard of Care in Lenalidomide-Refractory Multiple Myeloma: Phase 3 CARTITUDE-4 Study Update
Prevent Infusion-Related Reactions With Intravenous Amivantamab: Primary Results From SKIPPirr, a Phase 2 Study
Amivantamab Plus Lazertinib vs Osimertinib in First-Line EGFR-Mutant Advanced NSCLC: Longer Follow-Up of the MARIPOSA Study
Pelabresib in Myelofibrosis: Exploring Disease Modification and Immune Response
Between the Lines: Recent Updates in Treatment and Strategies for Managing Adverse Events in Multiple Myeloma
IMbrave150: Atezolizumab plus Bevacizumab in HCC: Efficacy Data and Clinical Practice Implications
Exploring the Dynamics of ctDNA as a Predictive Biomarker of Recurrent Disease in Post-Operative Patients with Colorectal Cancer (CRC)
Acalabrutinib Plus Bendamustine and Rituximab in Untreated MCL: Results From the Phase 3 ECHO Trial
ASCO 2024 Updates in the Treatment of Renal Cell Carcinoma and Evolving Data on Non-Clear Cell Renal Cell Carcinoma
DARA + VRd in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Analysis of Minimal Residual Disease in the PERSEUS Trial
Long-Term Follow-Up from the Phase 1/2 MajesTEC-1 trial of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma
Amivantamab plus chemotherapy with or without lazertinib in EGFR- mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated Non-Small-Cell Lung Cancer
Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome With Teclistamab Administration
Practical Management of Patients With Relapsed/Refractory Multiple Myeloma Receiving Talquetamab, a GPRC5DxCD3 Bispecific Antibody: Experience in MonumenTAL-1
Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
A Matching-Adjusted Indirect Comparison of Acalabrutinib Versus Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
Overview of Incidence and Management of CRS Observed With Teclistamab in the MajesTEC-1 Study of Patients With Relapsed/Refractory Multiple Myeloma
Evolving Treatment Landscape in Relapsed/Refractory Multiple Myeloma: MonumenTAL-1 and RedirecTT-1
Nivolumab plus Cabozantinib Versus Sunitinib for First-line Treatment of Advanced Renal Cell Carcinoma: 3-year Follow-up from the Phase 3 CheckMate 9ER Trial
Amivantamab vs Alternative Therapies in Patients with EGFR Exon 20–Mutated NSCLC
Discussing Post Hoc Analyses from the REACH2 Trial
Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)